舒血宁注射液辅助治疗糖尿病肾病患者的疗效及安全性  

Efficacy and safety of Shuxuening injection as an adjuvant therapy for patients with diabetic nephropathy

作　　者：刘娜[1] 李少阳 荆鹏伟[3] 燕金霞 LIU Na;LI Shaoyang;JIN Pengwei;YAN Jinxia(Department of Pharmacy,Zhengzhou First People's Hospital,Zhengzhou 450000,China;Department of Clinical Laboratory,Zhengzhou First People's Hospital,Zhengzhou 450000,China;The First Affiliated Hospital of Henan University of CM,Zhengzhou 450003,China)

机构地区：[1]郑州市第一人民医院药学部,郑州450000 [2]郑州市第一人民医院检验科,郑州450000 [3]河南中医药大学第一附属医院检验科,郑州450003

出　　处：《华夏医学》2025年第1期101-106,共6页Acta Medicinae Sinica

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20211066)。

摘　　要：目的探讨舒血宁注射液联合依帕司他片治疗糖尿病肾病(DN)的临床疗效及应用价值。方法104例DN患者依据治疗方案分为对照组(依帕司他片治疗)和研究组(舒血宁注射液联合依帕司他片治疗),每组各52例。统计对比两组临床疗效、不良反应及治疗前后血糖、肾功能、炎症因子、细胞免疫(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))。结果研究组总有效率为88.46%,明显高于对照组的73.08%,差异具有统计学意义(P<0.05);与对照组比较,研究组治疗后空腹血糖(FBG)、餐后2 h血糖(2 hPBG)、尿白蛋白排泄率(UAER)、血尿素氮(BUN)水平降低,血肌酐(Scr)、内生肌酐清除率(CCr)水平升高(P<0.05);与对照组比较,研究组治疗后血清TGF-β1、IGF-1、VEGF、IL-6、hs-CRP、TNF-α水平降低(P<0.05);与对照组比较,研究组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)升高(P<0.05);两组不良反应比较无明显差异(P>0.05)。结论舒血宁注射液联合依帕司他片治疗DN患者,可提高临床疗效,降低血糖水平,改善肾功能,抑制炎症反应,提高机体免疫力,且具有一定安全性。Objective To explore the clinical efficacy and application value of Shuxuening injection combined with epalrestat tablets in the treatment of diabetic nephropathy(DN).Methods 104 patients with DN were divided into the control group(treated with epalrestat tablets)and study group(treated with Shuxuening injection combined with epalrestat tablets),with 52 cases in each group according to the treatment plan.The clinical efficacy,adverse effects,and blood glucose,renal function,inflammatory factors,and cellular immunity(CD3^(+),CD4^(+),CD 4^(+)/CD8^(+))were compared.Results The total effective rate of the study group was 88.46[FGS]%[FGN],significantly higher than 73.08[FGS]%[FGN]of the control group(P<0.05).Compared with the control group,fasting blood glucose(FBG),2 h postprandial blood glucose(2 h PBG),urinary albumin excretion rate(UAER),blood urea nitrogen(BUN)levels decreased,blood creatinine(Scr),endogenous creatinine clearance(CCr)levels increased in the study group(P<0.05).Compared with the control group,the study group showed reduced levels of serum TGF-β1,IGF-1,VEGF,IL-6,hs-CRP,and TNF-αafter treatment(P<0.05).Compared with the control group,the CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)levels in the study group were increased after treatment(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of Shuxuening injection and epalrestat tablets can improve clinical efficacy,reduce blood glucose levels,improve renal function,inhibit inflammatory reactions,enhance immune function,and have certain safety in the treatment of DN patients.

关 键 词：糖尿病肾病 依帕司他片 舒血宁注射液 疗效 肾功能 炎症因子 

分 类 号：R587.2[医药卫生—内分泌]